#COVID19 #VariantDashboard - #USA| 10/01/2026 #SARSCoV2 #Lineages #30DAYTRENDS SW.2.1 (21.3%) PJ.2.1 (7.6%) RW.1.1.2 (7.6%) TA.1 (5.3%) RF.5.4.1 (4.8%) RV.1.1 (3.8%) RV.1.3 (3.7%) SB.1.1.1 (3.3%) XFG.1.1.3 (2.4%) RW.1.1.1 (2.2%) RE.2.5 (2.1%) Tracker tinyurl.com/mryj4uu7

Tracking #SARSCoV2 #Lineages - Globally | 10/02/2026 Top lineages -#30DayTrends #G30 ST.1 (11.1%) SW.2.1 (9.8%) TA.1 (5.2%) PJ.2.1 (4.8%) TK.1 (4.5%) RW.1.1.2 (3.9%) RK.1.5 (3.4%) RV.1.3 (3.3%) RF.5.4.1 (2.5%) SV.1.2 (2.4%) Tracker: public.tableau.com/app/profile/... 1/n

Lp(a)HORIZON failed. Did #COVID play a role? 1. Pelacarsen lowered Lp(a). Heart attacks and strokes didn't follow. 2. Six years of follow-up through a pandemic that moved the cardiovascular baseline for everyone in both arms www.novartis.com/news/media-r... 1/n

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

novartis.com

With this white coat, Class of 2030 NYITCOM at Arkansas State, begin your journey as physicians, scholars, and lifelong learners well grounded in evidence-based care, research and service to the Arkansas Delta and beyond.

Tracking #SARSCoV2 #Lineages - Globally | 07/18/2026 #30DayTrends Only #Singapore, #USA, and #Australia have submitted more than 100 sequences with collection dates in the last 30 days Tracker: public.tableau.com/app/profile/... 1/n

Tracking #SARSCoV2 #Lineages - Globally | 06/02/2026 #30DayTrends Only #Singapore, #Australia and #USA have submitted more than 100 sequences with collection dates in the last 30 days Tracker: public.tableau.com/app/profile/... 1/n

Tracking #SARSCoV2 #Lineages - Globally | 5/17/2026 #30DayTrends Only #Singapore, #Australia, #Canada and #USA has submitted more than 100 sequences with collection dates in the last 30 days Tracker: public.tableau.com/app/profile/ra… 1/n

Tracking #SARSCoV2 #Lineages - Globally | 3/30/2026 Top lineages -#30DayTrends #G30 XFG.1.1 (10.8%) PQ.2.8.1 (9.8%) PQ.2.1.3 (4.9%) PQ.17 (4.2%) RE.1.1 (4%) RE.2.2 (3.2%) PQ.2.1 (2.8%) PE.1.4 (2.7%) PY.1.1.1 (2.7%) Tracker: public.tableau.com/app/profile/... 1/n

#SARSCoV2 Lineage BA.3.2 #Cicada updates 03/26/2026 Tracking BA.3.2* sub-lineages BA.3.2* family has now 60 members! 1/n

Celebration of Research Excellence NYITCOM at A-State 6th Annual Research Symposium brought the halls to life with curiosity, courage, and discovery. Proud of our student investigators, faculty mentors, and guest judges who continue to advance impactful scholarship.

Tracking SARSCoV2 Lineage BA.3.2* #Cicada over time | 02/18/2026 Total BA.3.2* seqs: 1157 (+6) Top seq submitters: #Germany, #Netherlands, #Australia, #UnitedKingdom, #Denmark, #Ireland, #SouthAfrica BA.3.2* Tracker: public.tableau.com/app/profile/...

Is Clinical AI Leaving Osteopathic Medicine Behind? It may be time for clinical AI platforms like to undergo something we already expect in other domains: representation audits, fairness testing & transparent source benchmarking linkedin.com/posts/raj-ra...

#openevidence | Raj Rajnarayanan, PhD, FRSPH

When Clinical AI Becomes the New Authority… Who Gets Left Out? #OpenEvidence and other clinical AI tools are rapidly becoming the default “second opinion” for trainees and clinicians. They are fast,...

linkedin.com

Tracking SARSCoV2 Lineage BA.3.2* #Cicada over time | 01/17/2026 Total BA.3.2* seqs: 657 (+33) Top seq submitters: #Germany, #Australia, #Netherlands, #Denmark, #SouthAfrica, #UnitedKingdom BA.3.2* Tracker: public.tableau.com/app/profile/...

AI doesn’t replace people. It replaces “unprotected” tasks. www.linkedin.com/posts/raj-ra...

AI adoption is no longer about tools. It’s about task selection and signal management. Recent research shows that conversations with GenAI systems are used to assess AI adaptability. How employees… |...

AI adoption is no longer about tools. It’s about task selection and signal management. Recent research shows that conversations with GenAI systems are used to assess AI adaptability. How employees in...

linkedin.com

Happy Holidays from #NYITCOM office of research | follow the tag #NYITCOMResearch to celebrate #NYIT Faculty, Staff and Student’s research accomplishments

Tracking SARSCoV2 Lineage BA.3.2* ( #Cicada) over time | 12/15/25 Total BA.3.2* seqs: 184 (+4) Countries reporting BA.3.2*: #Australia, #SouthAfrica, #Netherlands, #USA, #Germany, #Mozambique, #Slovenia, #UK, #Denmark, #Ireland, #Singapore Tracker: public.tableau.com/app/profile/...

Tracking SARSCoV2 Lineage BA.3.2* ( #Cicada) over time | 12/05/25 Total BA.3.2* seqs: 118 (+1) Countries reporting BA.3.2*: #Australia, #SouthAfrica, #Netherlands, #USA (traveler seq), #Germany, #Mozambique, #Slovenia, #UK, #Denmark, #Ireland Tracker: public.tableau.com/app/profile/...

Tracking SARSCoV2 Lineage BA.3.2* over time | 11/19/2025 update Total BA.3.2* sequences: 91 Countries reporting BA.3.2*: #Australia, #SouthAfrica, #Netherlands, #USA (traveler seq), #Germany, #Mozambique, #Slovenia, #UK, #Denmark Tracker: public.tableau.com/app/profile/...

1/ 🚀 Big thanks to our community - since August we’ve added thousands of new sequences, rolled out major new features, and welcomed fresh faces into the #Pathoplexus world. Let’s dive into what’s new.👇🏻 Read the full update: pathoplexus.org/news/2025-11...

#H3N2 #FluUpdates 11/12/2025 Quick analysis of #H3N2 sequences (Subclade: K) uploaded from #Canada (#NewBrunswick) Key mutations: HA: T135K, S144N, N145S, N158D, I160K, A186D Reference: A/Croatia/10136RV/2023(H3N2) Collection dates: 20-31 Oct 2025

Tracking SARSCoV2 Lineage BA.3.2* over time Total BA.3.2* - Globally: 63 Countries reporting BA.3.2*: #Australia, #SouthAfrica, #Netherlands, #USA (traveler seq), #Germany, #Mozambique, #Slovenia, #UK, #Denmark Tracker: public.tableau.com/app/profile/...

#COVID19 #VariantDashboard - #USA| 11/07/25 #SARSCoV2 #Lineages #30DAYTRENDS XFG.2 (10.9%) XFG.3.4.1 (4.7%) XFG.3 (4.7%) XFG.14.1 (4.3%) XFG.4.1 (3.8%) XFG.5.1 (3.8%) XFG.5.2 (2.8%) XFG.3.4.3 (2.6%) XFG.6 (2.6%) XFG.3.4 (2.4%) Tracker tinyurl.com/mryj4uu7 1/n

Tracking #SARSCoV2 #Lineages - Globally |11/04/25 Top lineages -#30DayTrends #G30 XFG.3 (9.1%) XFG.3.4.1 (6.1%) XFG.2 (4.7%) XFG.5.1 (4.4%) NB.1.8.1 (3.5%) XFG (2.8%) XFG.4.1 (2.7%) XFG.6 (2.7%) XFG.8 (2.4%) XFG.5.2 (2.4%) Tracker: public.tableau.com/app/profile/... 1/n

Tracking #SARSCoV2 #Lineages - Globally |10/26/25 Top lineages -#30DayTrends #G30 XFG.3 (8.4%) XFG.3.4.1 (6.7%) XFG.5.1 (4.5%) NB.1.8.1 (4.4%) XFG.2 (3.6%) XFG (3.4%) XFG.4.1 (2.8%) XFG.8 (2.6%) XFG.6 (2.6%) XFG.3.4 (2.5%) Tracker: public.tableau.com/app/profile/... 1/n

Tracking #SARSCoV2 #Lineages - Globally |10/16/25 Top lineages -#30DayTrends #G30 XFG.3 (9.2%) NB.1.8.1 (5.3%) XFG.2 (5.3%) XFG.3.4.1 (4.8%) XFG.5.1 (3.8%) XFG.8 (3.2%) XFG.4.1 (2.9%) XFG (2.6%) XFG.6 (2.1%) PQ.17 (2%) Tracker: public.tableau.com/app/profile/... 1/n

#COVID19 #VariantDashboard - #USA| 09/14/25 #SARSCoV2 #Lineages #30DAYTRENDS XFG (35.9%) XFG.3 (24.8%) XFG.2 (14.2%) NB.1.8.1 (6.3%) PQ.2 (3.4%) XFG.3.1 (2.2%) LP.8.1.1 (1.4%) NW.1.2 (1.4%) NW.1 (1.1%) XFC (1.1%) PY.1 (0.8%) Tracker: tinyurl.com/mryj4uu7 1/n

Tracking #SARSCoV2 #Lineages - Globally |09/14/25 Top lineages -#30DayTrends #G30 XFG (32.1%) XFG.3 (23%) NB.1.8.1 (13.3%) XFG.2 (5.2%) PQ.2 (4.5%) XFG.3.1 (3.3%) PE.1 (2.4%) PQ.1 (1.1%) PQ.10 (1.1%) LP.8.1.1 (1%) Tracker: public.tableau.com/app/profile/... 1/n

#COVID19 #VariantDashboard - #USA| 09/08/25 #SARSCoV2 #Lineages #30DAYTRENDS XFG (34.4%) XFG.3 (22.2%) XFG.2 (15.4%) NB.1.8.1 (7.1%) PQ.2 (3.6%) NW.1.2 (2.8%) XFG.3.1 (1.9%) LP.8.1.1 (1.2%) PQ.1 (0.9%) Tracker: tinyurl.com/mryj4uu7 1/n

Tracking #SARSCoV2 #Lineages - Globally |09/01/25 Top lineages -#30DayTrends #G30 XFG (31.5%) XFG.3 (20%) NB.1.8.1 (13.4%) XFG.2 (6%) PQ.2 (5%) XFG.3.1 (3.5%) PQ.1 (1.8%) LP.8.1.1 (1.3%) PQ.10 (1.3%) MC.10.2.1 (1.2%) Tracker: public.tableau.com/app/profile/... 1/n

#COVID19 #VariantDashboard - #USA| 08/28/25 #SARSCoV2 #Lineages #30DAYTRENDS XFG (23.5%) XFG.3 (23.3%) XFG.2 (18%) NB.1.8.1 (6.8%)⬇️ PQ.2 (3.8%) LP.8.1.1 (2.1%) NW.1.2 (1.6%) PY.1 (1.6%) XFG.3.1 (1.5%) PQ.1 (1.2%) Tracker: tinyurl.com/mryj4uu7 1/n